Protherics Archive

Protherics Archive

Protherics Archive

Offer Update: Court Confirmation of Reduction of Capital
3 December 2008
Further to the announcement dated 1 December 2008, Protherics (LSE: PTI) and BTG plc ("BTG") (LSE: BGC) are pleased to announce that the High Court of Justice in England and Wales has today made an order confirming the reduction of Portherics' share capital in connection with the Scheme of Arrangement by which BTG's Acquisition of Protherics is being implemented. This follows the Court's sanction of the Scheme at a hearing held on 1 December 2008
More Information

Offer Update: Court Sanction of Scheme of Arrangement
1 December 2008
Protherics (LSE: PTI) and BTG plc ("BTG") (LSE: BGC) are pleased to announce that the High Court of Justice in England and Wales has today made an order sanctioning the Scheme of Arrangement by which BTG's Acquisition of Protherics is being implemented.
More Information

Holding in Company
20 November 2008
London, UK; Brentwood, TN, US: 20 November 2008 - Protherics PLC ("Protherics" or the "Company"), the international biopharmaceutical company focused on critical care and cancer, announces that, on 19 November 2008, in accordance with the Transparency Obligations Directive, a notification of interest in the ordinary share capital of the Company was received from AXA Investment Managers UK Limited on behalf of AXA S.A. and its Group Companies ("AXA").
More Information

Holding in Company
20 November 2008
London, UK; Brentwood, TN, US; 20 November 2008 - Protherics PLC ("Protherics" or the "Company"), the international biopharmaceutical company focused on critical care and cancer, announces that, on 19 November 2008, the following notification of interest in the ordinary share capital of the Company was received from Aviva plc.
More Information

Notice of Interim Results
12 November 2008
London, UK; Brentwood, TN, US; 12 November 2008: Protherics PLC ("Protherics"), the biopharmaceutical company focused on critical care and cancer, will be announcing its interim results for the six months ended 30 September 2008, on Thursday 20 November 2008.
More Information

Results of Protherics Shareholder Meetings
11 November 2008
Further to the announcement made by Protherics on 17 October 2008 regarding the posting of the Scheme Document in relation to the recommended all share offer by BTG plc ("BTG") for Protherics (the "Recommended Offer"), the Independent Directors of Protherics are pleased to announce that the Court Meeting and EGM held earlier today to approve the Scheme of Arrangement by which the Recommended Offer is being implemented have both concluded successfully.
More Information

Total Voting Rights
3 November 2008
London, UK; Brentwood, TN; 3 November 2008 - In conformity with the Transparency Directive, Protherics PLC ("Protherics"), the international biopharmaceutical company focused on critical care and cancer, notifies the market of the following:
More Information

Holding in Company
28 October 2008
London, UK; Brentwood, TN, US; 28 October 2008 - Protherics PLC ("Protherics" or the "Company"), the international biopharmaceutical company focused on critical care and cancer, announces that the following notification of interest in the ordinary share capital of the Company was received today from Aviva plc.
More Information

Director Dealings
28 October 2008
London, UK; Brentwood, TN, US: 28 October 2008 - Protherics PLC ("Protherics" or the "Company"), the international biopharmaceutical company focused on critical care and cancer, in accordance with the FSA Disclosure and Transparency Rules, announces that, on 23 October 2008, pursuant to the conversion of all outstanding six per cent. unsecured convertible loan notes 2010 of Protherics, the following ordinary shares (the "Shares") were allotted to Directors of Protherics PLC:
More Information

Holding in Company
27 October 2008
London, UK; Brentwood, TN, US: 27 October 2008 - Protherics PLC ("Protherics" or the "Company"), the international biopharmaceutical company focused on critical care and cancer, announces that on 27 October 2008, in accordance with the Transparency Obligations Directive, a notification of interest in the ordinary share capital of the Company was received from AXA Investment Managers UK Limited on behalf of AXA S.A. and its Group Companies ("AXA"). Details of the interest notified are set out below.
More Information

Rule 2.10 Announcement
24 October 2008
London, UK; Brentwood, TN, US: 24 October 2008 - Protherics PLC ("Protherics" or the "Company"), the international biopharmaceutical company focused on critical care and cancer, confirms, in accordance with Rule 2.10 of the City Code on Takeovers and Mergers (the "Code"), that as at the close of business on 23 October 2008, the Company has 350,427,481 ordinary shares of 2 pence each in issue and admitted to trading on the London Stock Exchange under the UK ISIN Code GB0007029209.
More Information

Offer Update
17 October 2008
Further to the announcement of the recommended all share offer by BTG plc ("BTG") for Protherics on 18 September 2008 (the "Recommended Offer"), the board of BTG and the Independent Protherics Directors are pleased to announce that the Scheme Document relating to the Recommended Offer is being posted to Protherics Shareholders today, together with a copy of the BTG Prospectus relating to the New BTG Shares to be issued in connection with the Recommended Offer. In addition, the BTG Prospectus and BTG Circular are today being sent to BTG Shareholders.
More Information

Offer update
16 October 2008
Further to the announcement of the recommended all share offer by BTG for Protherics on 18 September 2008 (the "Recommended Offer"), the board of BTG and the Independent Directors of Protherics hereby announce that the Scheme Document relating to the Recommended Offer will be sent to Protherics Shareholders on 17 October 2008, together with a copy of the BTG Prospectus relating to the New BTG Shares to be issued in connection with the Recommended Offer.
More Information

Rule 2.10 Announcement
10 October 2008
London, UK; Brentwood, TN, US: 10 October 2008 - Protherics PLC ("Protherics" or the "Company"), the international biopharmaceutical company focused on critical care and cancer, in accordance with Rule 2.10 of the City Code on Takeovers and Mergers (the "Code"), confirms that as at the close of business on 9 October 2008, the Company has 342,560,165 ordinary shares of 2 pence each in issue and admitted to trading on the London Stock Exchange under the UK ISIN Code GB0007029209.
More Information

SAYE Blocklisting
9 October 2008
London, UK; Brentwood, TN; 9 October 2008 - Protherics PLC ("Protherics" or the "Company"), the international biopharmaceutical company focused on critical care and cancer, in accordance with Listing Rule 3.5.6, notifies the following details in respect of the block listing for its 1998 Savings Related Share Option Scheme:
More Information

Unapproved Share Option Scheme
9 October 2008
London, UK; Brentwood, TN; 9 October 2008 - Protherics PLC ("Protherics" or the "Company"), the international biopharmaceutical company focused on critical care and cancer, in accordance with Listing Rule 3.5.6, notifies the following details in respect of the block listing for its Unapproved Share Option Scheme:
More Information

Approved Blocklisting
9 October 2008
London, UK; Brentwood, TN; 9 October 2008 - Protherics PLC ("Protherics" or the "Company"), the international biopharmaceutical company focused on critical care and cancer, in accordance with Listing Rule 3.5.6, notifies the following details in respect of the block listing for its Approved Share Option Scheme:
More Information

Individual Blocklisting
9 October 2008
London, UK; Brentwood, TN; 9 October 2008 - Protherics PLC ("Protherics" or the "Company"), the international biopharmaceutical company focused on critical care and cancer, in accordance with Listing Rule 3.5.6, notifies the following details in respect of the block listing for its Individual Unapproved share option arrangements:
More Information

Rule 2.10 Announcement
7 October 2008
London, UK; Brentwood, TN, US: 7 October 2008 - Protherics PLC ("Protherics" or the "Company"), the international biopharmaceutical company focused on critical care and cancer, in accordance with Rule 2.10 of the City Code on Takeovers and Mergers (the "Code"), confirms that as at the close of business on 6 October 2008, the Company has 342,450,241 ordinary shares of 2 pence each in issue and admitted to trading on the London Stock Exchange under the UK ISIN Code GB0007029209.
More Information

Total Voting Rights
2 October 2008
London, UK; Brentwood, TN; 2 October 2008 - In conformity with the Transparency Directive, Protherics PLC ("Protherics"), the international biopharmaceutical company focused on critical care and cancer, notifies the market of the following:
More Information

Holding in Company
9 September 2008
London, UK; Brentwood, TN, US: 9 September 2008 - Protherics PLC ("Protherics" or the "Company"), the international biopharmaceutical company focused on critical care and cancer, announces that on 8 September 2008, in accordance with the Transparency Obligations Directive, a notification of interest in the ordinary share capital of the Company was received from AXA Investment Managers UK Limited on behalf of AXA S.A. and its Group Companies ("AXA"). The notification follows a change in AXA's Indirect Voting Rights. Details of the interest notified are as follows:
More Information

6 Month Block Listing return
9 September 2008
London, UK; Brentwood, TN; 9 September 2008 - Protherics PLC ("Protherics" or the "Company"), the international biopharmaceutical company focused on critical care and cancer, in accordance with Listing Rule 3.5.6, notifies the following details in respect of the block listing for its Long Term Incentive Plan and Deferred Bonus Plan:
More Information

Holding in Company
3 September 2008
London, UK; Brentwood, TN, US: 3 September 2008 - Protherics PLC ("Protherics" or the "Company"), the international biopharmaceutical company focused on critical care and cancer, announces that on 2 September 2008, in accordance with the Transparency Obligations Directive, a notification of interest in the ordinary share capital of the Company was received from Citigroup on behalf of Standard Life Investments Ltd. Details of the interest notified are as follows:
More Information

Total Voting Rights
2 September 2008
London, UK; Brentwood, TN; 2 September 2008 - In conformity with the Transparency Directive, Protherics PLC ("Protherics"), the international biopharmaceutical company focused on critical care and cancer, notifies the market of the following:
More Information

Holding in Company
29 August 2008
London, UK; Brentwood, TN, US: 29 August 2008 - Protherics PLC ("Protherics" or the "Company"), the international biopharmaceutical company focused on critical care and cancer, announces that today, in accordance with the Transparency Obligations Directive, a notification of interest in the ordinary share capital of the Company was received from Invesco Perpetual on behalf of Invesco Limited. Details of the interest notified are as follows:
More Information

Holding in Company
14 August 2008
London, UK; Brentwood, TN, US: 14 August 2008 - Protherics PLC ("Protherics" or the "Company"), the international biopharmaceutical company focused on critical care and cancer, announces that on 13 August 2008, in accordance with the Transparency Obligations Directive, a notification of interest in the ordinary share capital of the Company was received from AXA Investment Managers UK Limited on behalf of AXA S.A. and its Group Companies ("AXA"). The notification follows an increase in its Indirect Voting Rights. Details of the interest notified are as follows:
More Information

Holding in Company
14 August 2008
London, UK; Brentwood, TN, US; 14 August 2008 - Protherics PLC ("Protherics" or the "Company"), the international biopharmaceutical company focused on critical care and cancer, announces that, on 12 August 2008, the following notification of interest in the ordinary share capital of the Company was received today from Aviva plc.
More Information

Rule 2.10 Announcement
14 August 2008
London, UK; Brentwood, TN, US; 14 August 2008

In accordance with Rule 2.10 of the City Code on Takeovers and Mergers (the "Code"), Protherics confirms that at the close of business on 13 August 2008, it has 342,159,034 ordinary shares of 2 pence each in issue and admitted to trading on the London Stock Exchange under the UK ISIN code GB0007029209.

The ISIN number above corrects that cited in the Rule 2.4 announcement issued by the Company on 13 August 2008.
More Information

Block Listing Six Monthly Return
8 August 2008
London, UK; Brentwood, TN, US: 8 August 2008 - Protherics PLC ("Protherics" or the "Company"), the international biopharmaceutical company focused on critical care and cancer, in accordance with Listing Rule 3.5.6, notifies the following details in respect of a block listing for the Company's 6% Unsecured Convertible Loan Notes:
More Information

Holding in Company
8 August 2008
London, UK; Brentwood, TN, US; 8 August 2008 - Protherics PLC ("Protherics" or the "Company"), the international biopharmaceutical company focused on critical care and cancer, announces that the following notification of interest in the ordinary share capital of the Company was received today from Aviva plc.
More Information

Documents filed with the UK Listing Authority
25 July 2008
In accordance with LR 9.6.2, Protherics PLC ("Protherics" or the "Company"), the international biopharmaceutical company focused on critical care and cancer, has today forwarded for publication through the Document Viewing Facility, copies of all resolutions passed under Special business at the Company's Annual General Meeting held on 22 July 2008.
More Information

Annual Information Update
25 July 2008
In accordance with Prospectus Rule 5.2, Protherics PLC ("Protherics" or the "Company"), the international biopharmaceutical company focused on critical care and cancer, sets out below a list of the information that has been published or made available to the public during the period beginning 20 July 2007 up to and including 24 July 2008.
More Information

2008 Annual General Meeting Results
22 July 2008
London, UK; Brentwood, TN, US: 22 July 2008 - Protherics PLC (the "Company"), the international biopharmaceutical company focused on critical care and cancer, is pleased to announce that Resolutions 1 to 7 and 9 to 11 put forward at the Annual General Meeting of the Company held earlier today were passed. Since Resolution 7 was passed, Resolution 8 was withdrawn.
More Information

Interest in Shares
4 July 2008
London, UK; Brentwood, TN, US: 4 July 2008 - Protherics PLC ("Protherics" or the "Company"), the international biopharmaceutical company focused on critical care and cancer, announces that on 3 July 2008, in accordance with the Transparency Obligations Directive, a notification of interest in the ordinary share capital of the Company was received from AXA Investment Managers UK Limited on behalf of AXA S.A. and its Group Companies ("AXA"). The notification follows a disposal of voting rights.
More Information

Issue of Shares
4 July 2008
London, UK; Brentwood, TN, US: 4 July 2008 - Protherics PLC ("Protherics" or the "Company"), the international biopharmaceutical company focused on critical care and cancer, announces that the Company has today issued 1,741,911 ordinary shares pursuant to the MacroMed Acquisition Agreement ("Agreement") approved by shareholders at the Company's Extraordinary General Meeting held on 3 January 2007 and details of which were contained in the Company's announcement dated 7 December 2006.
More Information

Total Voting Rights
2 July 2008
London, UK; Brentwood, TN; 2 July 2008 - In conformity with the Transparency Directive, Protherics PLC ("Protherics"), the international biopharmaceutical company focused on critical care and cancer, notifies the market of the following:
More Information

Documents lodged with the UK Listing Authority's Document Viewing Facility
24 June 2008
London, UK; Brentwood, TN, US: 24 June 2008 - Protherics PLC ("Protherics" or the "Company"), the international biopharmaceutical company focused on critical care and cancer, announces that the Company's Annual Report and Financial Statements for the year ended 31 March 2008, together with a Circular to Shareholders containing the Notice of the Company's Annual General Meeting to be held at 12.00 noon on Tuesday 22 July 2008 at the offices of Ashurst LLP, Broadwalk House, 5 Appold Street, London EC2A 2HA, have been posted to shareholders today.
More Information

Holding in Company
13 June 2008
London, UK; Brentwood, TN, US: 13 June 2008 - Protherics PLC ("Protherics" or the "Company"), the international biopharmaceutical company focused on critical care and cancer, announces that today, in accordance with the Transparency Obligations Directive, a notification of interest in the ordinary share capital of the Company was received from Invesco Perpetual on behalf of Perpetual Income and Growth Investment Trust. Details of the interest notified are as follows:
More Information

Directors Dealings
13 June 2008
London, UK; Brentwood, TN, US: 13 June 2008 - Protherics PLC ("Protherics" or the "Company"), the international biopharmaceutical company focused on critical care and cancer, announces the vesting, on 12 June 2008, of a Performance Share Award ("Award") to Saul Komisar, Director of Protherics PLC and President of Protherics Inc. under the terms of the Company's Deferred Bonus Plan. The Award was made on 12 June 2006 and vests two years from its Date of Grant.
More Information

Director Dealings
10 June 2008
London, UK; Brentwood, TN, US; 10 June 2008 - Protherics PLC ("Protherics" or the "Company"), the international biopharmaceutical company focused on critical care and cancer, Protherics PLC announces the grant, on 9 June 2008, of the following options over Ordinary Shares in Protherics ("Ordinary Shares") to Directors and other Persons Discharging Managerial Responsibility (PDMRs) under the terms of the Protherics PLC Long Term Incentive Plan ("LTIP"):
More Information

Director Share Purchases
3 June 2008
London, UK; Brentwood, TN; 3 June 2008 - Protherics PLC ("Protherics" or the "Company"), the international biopharmaceutical company focused on critical care and cancer, announces that today, in accordance with paragraph 3.1.2 of the FSA Disclosure and Transparency Rules, the Company received notification of the following dealings in the Ordinary share capital of the Company (Ordinary 2p Shares) by Directors and other Persons Discharging Managerial Responsibility (PDMRs), which took place on 3 June 2008:
More Information

Total Voting Rights
1 May 2008
London, UK; Brentwood, TN; 1 May 2008 - In conformity with the Transparency Directive, Protherics PLC ("Protherics"), the international biopharmaceutical company focused on critical care and cancer, notifies the market of the following:
More Information

Total Voting Rights
1 April 2008
London, UK; Brentwood, TN; 1 April 2008 - In conformity with the Transparency Directive, Protherics PLC ("Protherics"), the international biopharmaceutical company focused on critical care and cancer, notifies the market of the following:
More Information

Block Listing
5 March 2008
London, UK; Brentwood, TN, US: 6 March 2008 - Protherics PLC ("Protherics" or the "Company"), the international biopharmaceutical company focused on critical care and cancer, announces that today, application has been made to the UK Listing Authority and the London Stock Exchange for the block listing of 259,014 ordinary shares of 2p each in the Company (the "Shares") to be admitted to trading on the Official List and to trading on London Stock Exchange's main market. The Shares will be used to fulfil the Company's requirement to allot shares pursuant to the exercise of options under the terms of the Company's 2005 Long-Term Incentive Plan and 2005 Deferred Bonus Plan.
More Information

Total Voting Rights
4 March 2008
London, UK; Brentwood, TN; 4 March 2008 - In conformity with the Transparency Directive, Protherics PLC ("Protherics"), the international biopharmaceutical company focused on critical care and cancer, notifies the market of the following:
More Information

Notification of Major Interest in Shares
26 February 2008
London, UK; Brentwood, TN, US: 26 February 2008 - Protherics PLC ("Protherics" or the "Company"), the international biopharmaceutical company focused on critical care and cancer, announces that, on 25 February 2008, in accordance with the Transparency Obligations Directive, a notification of interest in the ordinary share capital of the Company was received from AXA Investment Managers UK Limited on behalf of AXA S.A. and its Group Companies ("AXA"). Details of the notification are as follows:
More Information

Block Listing Loan Notes
8 Feburary 2008
London, UK; Brentwood, TN, US: 8 February 2008 - Protherics PLC ("Protherics" or the "Company"), the international biopharmaceutical company focused on critical care and cancer, in accordance with Listing Rule 3.5.6, notifies the following details in respect of a block listing for the Company's 6% Unsecured Convertible Loan Notes:
More Information

 

2007

Notification of Major Interests in Shares
20 December 2007
London, UK; Brentwood, TN, US; 20 December 2007 - Protherics PLC ("Protherics" or the "Company"), the international biopharmaceutical company focused on critical care and cancer, announces that the following notification of interest in the ordinary share capital of the Company was received on 19 December 2007 from Legal & General Investment Management Ltd.
More Information

Total Voting Rights
3 December 2007
London, UK; Brentwood, TN; 3 December 2007 - In conformity with the Transparency Directive, Protherics PLC ("Protherics"), the international biopharmaceutical company focused on critical care and cancer, notifies the market of the following:
More Information

Application for Listing
29 November 2007
London, UK; Brentwood, TN, US: 29 November - Protherics PLC ("Protherics" or the "Company"), the international biopharmaceutical company focused on critical care and cancer, announces that today, application has been made to the UK Listing Authority and the London Stock Exchange for 253,211 ordinary shares of 2p each in the Company (the "Shares") to be admitted to trading on the Official List and to trading on London Stock Exchange's main market. The Shares have been allotted pursuant to the conversion of €300,000 in nominal value of convertible loan notes (the "Notes") issued to CoVaccine BV on 2 November 2007.
More Information

Notification of Directors' Interests
26 November 2007
London, UK; Brentwood, TN, US; 26 November 2007 - Protherics PLC ("Protherics" or the
“Company"), the international biopharmaceutical company focused on critical care and cancer, announces that, on 23 November 2007, a conditional right to receive 157,980 ordinary shares in Protherics ("Ordinary Shares") was awarded to Saul Komisar, President of Protherics Inc., under the terms of the Protherics PLC Long Term Incentive Plan (the "LTIP").
More information

Notification of PDMR Interests
26 November 2007
London, UK; Brentwood, TN, US; 26 November 2007 - Protherics PLC ("Protherics" or the
“Company"), the international biopharmaceutical company focused on critical care and cancer, announces that, on 23 November 2007, the following options over ordinary shares of 2 pence each in Protherics ("Ordinary Shares") were granted under the terms of the Company's Long Term Incentive Plan.
More information

Notification of Major Interests in Shares
23 November 2007
London, UK; Brentwood, TN, US: 23 November 2007 - Protherics PLC ("Protherics" or the "Company"), the international biopharmaceutical company focused on critical care and cancer, announces that on 22 November 2007, in accordance with the Transparency Obligations Directive, a notification of interest in the ordinary share capital of the Company was received from HBOS plc.
More information

Notification of Major Interests in Shares
19 November 2007
London, UK; Brentwood, TN, US: 19 November 2007 - Protherics PLC ("Protherics" or the
“Company"), the international biopharmaceutical company focused on critical care and cancer, announces that on 16 November 2007, in accordance with the Transparency Obligations Directive, a notification of interest in the ordinary share capital of the Company was received from AXA Investment Managers UK Limited on behalf of AXA S.A. and its Group Companies ("AXA").
More information

Notification of Interim Results
9 November 2007
London, 9 November 2007: Protherics PLC ("Protherics"), the biopharmaceutical company focused on critical care and cancer, will be announcing its interim results for the six months ended 30 September 2007, on Tuesday 20 November 2007.
More information

Issue of Loan Notes
2 November 2007
London, UK; Brentwood, TN; 2 November 2007 - Protherics PLC ("Protherics" or the Company"), the international biopharmaceutical company focused on critical care and cancer, announces that, today, €300,000 nominal value of Unsecured Convertible Loan Notes 2026 (the "Loan Notes") were issued to CoVaccine B.V. ("CoVaccine"), under the terms of an agreement between CoVaccine and Protherics for the acquisition of CoVaccine's novel adjuvant CoVaccine HT™, details of which were announced on 7 June 2006. The Loan Notes are issuable following the attainment of the first development related milestone represented by the agreement between Protherics and Nobilon International B.V. for the licensing of CoVaccine HT™ for use in pandemic influenza vaccines and seasonal influenza vaccines in elderly people.
More Information

Total Voting Rights and Share Capital
31 October 2007
London, UK; Brentwood, TN; 31 October 2007 - In conformity with the Transparency Directive, Protherics PLC ("Protherics"), the international biopharmaceutical company focused on critical care and cancer, notifies the market of the following:
More Information

Notification of Major Interests in Shares
30 October 2007
London, UK; Brentwood, TN, US: 30 October 2007 - Protherics PLC ("Protherics" or the "Company"), the international biopharmaceutical company focused on critical care and cancer, announces that on 29 October 2007, in accordance with the Transparency Obligations Directive, a notification of interest in the ordinary share capital of the Company was received from AXA Investment Managers UK Limited on behalf of AXA S.A. and its Group Companies ("AXA"). The notification follows a decrease in the Indirect holding of AXA.
More information

Notification of Major Interests in Shares
23 October 2007
London, UK; Brentwood, TN, US: 23 October 2007 - Protherics PLC ("Protherics" or the "Company"), the international biopharmaceutical company focused on critical care and cancer, announces that on 19 October 2007, in accordance with the Transparency Obligations Directive, a notification of interest in the ordinary share capital of the Company was received from AXA Investment Managers UK Limited on behalf of AXA S.A. and its Group Companies ("AXA"). Details of the interest notified are as follows:
More Information

6 monthly Block Listing Return
8 October 2007
London, UK; Brentwood, TN; 8 October 2007 - Protherics PLC ("Protherics" or the "Company"), the international biopharmaceutical company focused on critical care and cancer, announces that, today, the following 6 monthly block listing return in respect of the Company's Unapproved Share Option Scheme has been lodged with the FSA in accordance with Listing Rule 3.5.6.
More Information

6 monthly Block Listing Return
8 October 2007
London, UK; Brentwood, TN; 8 October 2007 - Protherics PLC ("Protherics" or the "Company"), the international biopharmaceutical company focused on critical care and cancer, announces that, today, the following 6 monthly block listing return in respect of the Company's Approved Executive Share Option Scheme has been lodged with the FSA in accordance with Listing Rule 3.5.6.
More Information

6 monthly Block Listing Return
8 October 2007
London, UK; Brentwood, TN; 8 October 2007 - Protherics PLC ("Protherics" or the "Company"), the international biopharmaceutical company focused on critical care and cancer, announces that, today, the following 6 monthly block listing return in respect of the Company's Savings Related Share Option Scheme has been lodged with the FSA in accordance with Listing Rule 3.5.6.
More Information

6 monthly Block Listing Return
8 October 2007
London, UK; Brentwood, TN; 8 October 2007 - Protherics PLC ("Protherics" or the "Company"), the international biopharmaceutical company focused on critical care and cancer, announces that, today, the following 6 monthly block listing return in respect of the Company's Individual Unapproved Share Option arrangements has been lodged with the FSA in accordance with Listing Rule 3.5.6.
More Information

Notification of Director's Interests
1 October 2007
London, UK; Brentwood, TN; 1 October 2007 - Protherics PLC ("Protherics" or the "Company"), the international biopharmaceutical company focused on critical care and cancer, today announces that, on 28 September 2007, in accordance with paragraph 3.1.2 of the FSA Disclosure and Transparency Rules, the Company received notification that, on 28 September 2007, Garry Watts, Non-executive Director of Protherics, acquired 40,000 ordinary 2p shares in the Company ("Ordinary Shares") at a price of 48.42 pence per share.
More Information

Total Voting Rights and Share Capital
28 September 2007
London, UK; Brentwood, TN; 28 September 2007 - In conformity with the Transparency Directive, Protherics PLC ("Protherics"), the international biopharmaceutical company focused on critical care and cancer, notifies the market of the following:
Protherics' issued share capital consists of 339,316,822 ordinary shares with a nominal value of 2 pence each, with voting rights. Protherics does not hold any ordinary shares in Treasury. Therefore, the total number of voting rights in Protherics is 339,316,822.
More Information

Notification of Major Interest in Shares
25 September 2007
London, UK; Brentwood, TN, US: 25 September 2007 - Protherics PLC ("Protherics" or the
“Company"), the international biopharmaceutical company focused on critical care and cancer, announces that, on 24 September 2007, in accordance with the Transparency Obligations Directive, a notification of interest in the ordinary share capital of the Company was received from Aviva plc. The notification follows an increase in the combined direct and indirect voting rights of Aviva plc and its subsidiaries to 12.05% of total voting rights.
More information

Notification of Major Interest in Shares
21 August 2007
London, UK; Brentwood, TN, US: 21 August 2007 - Protherics PLC ("Protherics" or the "Company"), the international biopharmaceutical company focused on critical care and cancer, announces that on 20 August 2007, in accordance with the Transparency Obligations Directive, a notification of interest in the ordinary share capital of the Company was received from AXA Investment Managers UK Limited on behalf of AXA S.A. and its Group companies ("AXA"). The notification follows an increase in the Indirect voting rights of AXA from 10.94% to 11.01% of total voting rights. Details of their interest are as follows:
More Information

Notification of Major Interests in Shares
16 August 2007
London, UK; Brentwood, TN, US: 16 August 2007 - Protherics PLC ("Protherics" or the "Company"), the international biopharmaceutical company focused on critical care and cancer, announces that on 15 August 2007 a notification of interest in the ordinary share capital of the Company was received from AXA Investment Managers UK Limited on behalf of AXA S.A. and its Group companies, in accordance with the Transparency Obligations Directive. Details of their interest are as follows:
More Information

Notification of Director's Interests
13 August 2007
London, UK; Brentwood, TN, US: 13 August 2007 - Protherics PLC ("Protherics" or the "Company"), the international biopharmaceutical company focused on critical care and cancer, announces that Rolf Soderstrom, who was appointed as Finance Director of the Company on 10 August 2007, has been granted options to subscribe for 423,076 ordinary shares in the Company under the terms of the Company's Long-Term Incentive Plan. The options were granted on 10 August 2007 and are exercisable between the third and tenth anniversary of the date of grant at a price of 2p per ordinary share, subject to the achievement of performance conditions.
More Information

6 monthly Block Listing Return
09 August 2007
London, UK; Brentwood, TN, US: 9 August 2007 - Protherics PLC ("Protherics" or the "Company"), the international biopharmaceutical company focused on critical care and cancer, announces that the following 6 monthly block listing return in respect of the Company's 6% unsecured convertible loan notes has been lodged with the FSA today, in accordance with Listing Rule 3.5.6.
More information

Total Voting Rights and Share Capital
31 July 2007
London, UK; Brentwood, TN; 31 July 2007 - In conformity with the Transparency Directive, Protherics PLC ("Protherics"), the international biopharmaceutical company focused on critical care and cancer, notifies the market of the following:
More Information

Notification of Major Interest in Shares
26 July 2007
London, UK; Brentwood, TN, US: 26 July 2007 - Protherics PLC ("Protherics" or the "Company"), the international biopharmaceutical company focused on critical care and cancer, announces that, on 24 July 2007, a notification of interest in the ordinary share capital of the Company was received from AXA Investment Managers UK Limited on behalf of AXA S.A. and its Group companies, in accordance with the Transparency Obligations Directive.
More Information

AGM Results
26 July 2007
London, UK; Brentwood, TN, US: 26 July 2007 - Protherics PLC ("Protherics" or the "Company"), the international biopharmaceutical company focused on critical care and cancer, announces the results of voting at the 2007 Annual General Meeting.
More Information

Annual Information Update
20 July 2007
London, UK; Brentwood, TN, US: 20 July 2007 - In accordance with Prospectus Rule 5.2, Protherics PLC ("Protherics" or the "Company"), the international biopharmaceutical company focused on critical care and cancer, sets out below a list of the information that has been published or made available to the public during the period beginning 15 July 2006 up to and including 19 July 2007.
More information

Total Voting Rights and Share Capital
29 June 2007
London, UK; Brentwood, TN; 29 June 2007 - In conformity with the Transparency
Directive, Protherics PLC ("Protherics"), the international biopharmaceutical company
focused on critical care and cancer, notifies the market of the following.
More information

Documents lodged with the UK Listing Authority's
27 June 2007
London, UK; Brentwood, TN; 27 June 2007 - Protherics PLC ("Protherics" or the "Company"), the international biopharmaceutical company focused on critical care and cancer, has today posted to shareholders its Annual Report for the year ended 31 March 2007, which contains a notice of the Company's Annual General Meeting to be held at 12.00 noon on Thursday 26 July 2007 at the offices of Ashurst, Broadwalk House, 5 Appold Street, London EC2A 2HA (the "Meeting").
More information

Notification of Major Interest in Shares
18 June 2007
London, UK; Brentwood, TN, US; 18 June 2007 - Protherics PLC ("Protherics" or the "Company"), the international biopharmaceutical company focused on critical care and cancer, announces that, on 18 June 2007, a notification of interest in the ordinary share capital of the Company was received from INVESCO plc in accordance with the Transparency Obligations Directive. Details of the interest are as follows:
More information

Notification of Directors' Interests
18 June 2007
London, UK; Brentwood, TN, US; 18 June 2007 - Protherics PLC ("Protherics" or the "Company"), the international biopharmaceutical company focused on critical care and cancer, today announces that, on 15 June 2007, in accordance with Sections 3.1.4R(1)(a) and 3.1.4R(1)(b) of the FSA Disclosure and Transparency Rules, the Company received notification that, on 15 June 2007, Garry Watts, Non-executive Director of Protherics, acquired 50,000 ordinary 2p shares in the Company at a price of 58.5 pence per share.
More information

Notification of PDMR Interests
12 June 2007
London, UK; Brentwood, TN, US; 12 June 2007 - Protherics PLC ("Protherics" or the
“Company"), the international biopharmaceutical company focused on critical care and cancer, today announces that, on 11 June 2007, the following options over ordinary shares in the Company ("Ordinary Shares") were granted under the terms of the Protherics PLC Long Term Incentive Plan at an exercise price of 2 pence per share:
More information

Notification of Directors' Interests
12 June 2007
London, UK; Brentwood, TN, US; 12 June 2007 - Protherics PLC ("Protherics" or the
“Company"), the international biopharmaceutical company focused on critical care and cancer, today announces the award, on 11 June 2007, of a conditional right to receive
151,396 ordinary shares in Protherics ("Ordinary Shares") at a price of 2 pence each under the terms of the Protherics PLC 2005 Long Term Incentive Plan (the "LTIP"), to Saul
Komisar, President of the Company's US operations.
More information

Notification of Major Interest in Shares
4 June 2007
London, UK; Brentwood, TN, US; 4 June 2007 - Protherics PLC ("Protherics" or the "Company"), the international biopharmaceutical company focused on critical care and cancer, announces that, on 1 June 2007, a notification of interest in the ordinary share capital of the Company was received from Aviva plc as follows:
More information

Total Voting Rights and Share Capital
31 May 2007
London, UK; Brentwood, TN; 31 May 2007 - In conformity with the Transparency Directive, Protherics PLC ("Protherics"), the international biopharmaceutical company focused on critical care and cancer, notifies the market of the following:
More information

Total Voting Rights and Share Capital
30 April 2007
London, UK; Brentwood, TN; 30 April 2007 - In conformity with the Transparency Directive, Protherics PLC ("Protherics"), the international biopharmaceutical company focused on critical care and cancer, notifies the market of the following:
More information

Notification of Major Interest in Shares
27 April 2007
London, UK; Brentwood, TN, US; 27 April 2007 - Protherics PLC ("Protherics" or the"Company"), the international biopharmaceutical company focused on critical care andcancer, announces that the following notification of interest in the ordinary share capital ofthe Company was received on 26 April 2007 from Aviva plc.
More information

6 monthly Block Listing Return Unapproved Share Option Scheme
10 April 2007
London, UK; Brentwood, TN, US: 10 April 2007 - Protherics PLC ("Protherics" or the"Company"), the international biopharmaceutical company focused on critical care andcancer, announces that, today, the following 6 monthly block listing return in respect of theCompany's Unapproved Share Option Scheme has been lodged with the FSA in accordancewith Listing Rule 3.5.6.
More information

6 monthly Block Listing Return Savings Related Share Option Scheme
10 April 2007
London, UK; Brentwood, TN, US: 10 April 2007 - Protherics PLC ("Protherics" or the "Company"), the international biopharmaceutical company focused on critical care and cancer, announces that, today, the following 6 monthly block listing return in respect of the Company's Savings Related Share Option Scheme has been lodged with the FSA in accordance with Listing Rule 3.5.6.
More information

6 monthly Block Listing Return Approved Executive Share Option Scheme
10 April 2007
London, UK; Brentwood, TN, US: 10 April 2007 - Protherics PLC ("Protherics" or the"Company"), the international biopharmaceutical company focused on critical care andcancer, announces that the following 6 monthly block listing return in respect of theCompany's Approved Executive Share Option Scheme has been lodged with the FSA today,in accordance with Listing Rule 3.5.6.
More information

6 monthly Block Listing Return Individual Unapproved Options
10 April 2007
London, UK; Brentwood, TN, US: 10 April 2007 - Protherics PLC ("Protherics" or the"Company"), the international biopharmaceutical company focused on critical care andcancer, announces that, today, the following 6 monthly block listing return in respect of theCompany's Individual Unapproved Option arrangements has been lodged with the FSA inaccordance with Listing Rule 3.5.6.
More information

Total Voting Rights and Share Capital
30 March 2007
London, UK; Brentwood, TN; 30 March 2007 - In conformity with the Transparency
Directive, Protherics PLC ("Protherics"), the international biopharmaceutical company
focused on critical care and cancer, notifies the market of the following:
More information

Notification of Major Interests in Shares
21 March 2007
London, UK; Brentwood, TN, US: 21 March 2007 - Protherics PLC ("Protherics" or the "Company"), the international biopharmaceutical company focused on critical care and cancer, announces that, on 20 March 2007, the following notification of interest in the ordinary share capital of the Company was received from HBOS plc pursuant to the
Transparency Obligations Directive (Disclosure and Transparency Rules) Instrument 2006:
More information

Notification of Major Interests in Shares
19 March 2007
London, UK; Brentwood, TN, US: 19 March 2007 - Protherics PLC ("Protherics" or the"Company"), the international biopharmaceutical company focused on critical care andcancer, announces that, on 16 March 2007, a notification of interest in the ordinary sharecapital of the Company was received from AXA Investment Managers Limited on behalf ofAXA S.A. in accordance with the Transparency Obligations Directive. Details of the interestnotified are as follows:
More information

Notification of Major Interests in Shares
16 March 2007
London, UK; Brentwood, TN, US: 16 March 2007 - Protherics PLC ("Protherics" or the"Company"), the international biopharmaceutical company focused on critical care andcancer, announces that the following notification of interest in the ordinary share capital ofthe Company was received on 15 March 2007 from M&G Investment Management Limitedon behalf of Prudential plc pursuant to the Transparency Obligations Directive (Disclosureand Transparency Rules) Instrument 2006.
More information

Total Voting Rights and Share Capital
28 February 2007
London, UK; Brentwood, TN; 28 February 2007 - In conformity with the TransparencyDirective, Protherics PLC ("Protherics"), the international biopharmaceutical companyfocused on critical care and cancer, notifies the market of the following:
More information

Notification of Major Interest in Shares
27 February 2007
London, UK; Brentwood, TN, US; 27 February 2007 - Protherics PLC ("Protherics" or the "Company"), the international biopharmaceutical company focused on critical care and cancer, announces that the following notification of interest in the ordinary share capital of the Company was received on 26 February 2007 from Legal & General Group Plc.
More information

Notification of Major Interest in Shares
26 February 2007
London, UK; Brentwood, TN, US; 26 February 2007 - Protherics PLC ("Protherics" or the"Company"), the international biopharmaceutical company focused on critical care andcancer, announces that the following notification of interest in the ordinary share capital ofthe Company was received on 23 February 2007 from AMVESCAP PLC.
More information

6 monthly Block Listing Return in respect of 6% unsecured convertible loan notes
9 February 2007
London, UK; Brentwood, TN, US: 9 February 2007 - Protherics PLC ("Protherics" or the "Company"), the international biopharmaceutical company focused on critical care and cancer, announces that the following 6 monthly block listing return in respect of the Company's 6% unsecured convertible loan notes has been lodged with the FSA today, in accordance with Listing Rule 3.5.6.
More information

Total Voting Rights and Share Capital
31 January 2007
London, UK; Brentwood, TN; 31 January 2007 - In conformity with the Transparency Directive, Protherics PLC ("Protherics"), the international biopharmaceutical company focused on critical care and cancer, notifies the market of the following:
More information

Notification of Major Interest in Shares
30 January 2007
London, UK; Brentwood, TN, US; 30 January 2007 - Protherics PLC ("Protherics" or the "Company"), the international biopharmaceutical company focused on critical care and
cancer, announces that the following notification of interest in the ordinary share capital of the Company was received on 29 January 2007 from Aviva plc.
More information

Notification of Major Interest in Shares
22 January 2007
London, UK; Brentwood, TN, US: 22 January 2008 - Protherics PLC ("Protherics" or the "Company"), the international biopharmaceutical company focused on critical care and cancer, announces that, on 21 January 2008, in accordance with the Transparency Obligations Directive, a notification of interest in the ordinary share capital of the Company was received from AXA Investment Managers UK Limited on behalf of AXA S.A. and its Group Companies ("AXA"). Details of the notification are as follows:
More Information

Notification of major interest in shares
17 January 2007
London, UK; Brentwood, TN, US; 17 January 2007 - Protherics PLC ("Protherics" or the "Company"), the international biopharmaceutical company focused on critical care and cancer, today announces that, on 16 January 2007, notification was received from Artemis Investment Management Limited that, following the increase in the share capital of Protherics which took place on 4 January 2007, Artemis Income as beneficial owners of the shares within Artemis Investment Management Ltd, no longer have a notifiable interest in the shares of Protherics.
More information

Notification of Interest in Shares
8 January 2007
London, UK; Brentwood, TN, US; 8 January 2007 - Protherics PLC ("Protherics" or the "Company"), the international biopharmaceutical company focused on critical care and cancer, today announces that on 5 January 2007, notification was received from Perpetual Income & Growth Investment Trust plc ("Perpetual") that, following the recent placing of shares by the Company, Perpetual is the beneficial owner of 14,348,079 Ordinary Shares of 2p each in Protherics (4.23% of the issued share capital of the Company). The shares are registered in the name of Vidacos Nominees Limited.
More information

Notification of Major Interest in Shares
8 January 2007
London, UK; Brentwood, TN, US; 8 January 2007 - Protherics PLC ("Protherics" or the "Company"), the international biopharmaceutical company focused on critical care and cancer, announces that notification was received today from Aviva plc that, following the purchase of 3,738,187 Ordinary 2p shares in Protherics on 4 January 2007 (1.10% of the Company's issued share capital), Aviva plc and its subsidiaries hold an interest in 40,095,830 Ordinary Shares (11.83%).
More information

Total Voting Rights and Share Capital
4 January 2007
London, UK; Brentwood, TN; 4 January 2007. In conformity with the Transparency Directive's transitional provision 6, Protherics PLC ("Protherics"), the international biopharmaceutical company focused on critical care and cancer, is required to notify the market of the following:

Protherics' issued share capital consists of 338,976,174 ordinary shares with a nominal value of 2 pence each, with voting rights. Protherics does not hold any ordinary shares in Treasury.

Therefore, the total number of voting rights in Protherics is 338,976,174.

The above figure of 338,976,174 shares may be used by shareholders as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change to their interest in, Protherics under the Financial Service Authority's Disclosure and Transparency Rules.
More information

Notification Of Interests Of Directors
4 January 2007
London, UK; Brentwood, TN, US; 4 January 2007: Protherics PLC ("Protherics" or the "Company"), the international biopharmaceutical company focused on critical care and cancer, announces that following completion of the Cash Placing, the Placing and Open Offer, the Glenveigh Licence and the MacroMed Acquisition and as a result of the Directors taking up all of their entitlements under the Placing and Open Offer at a price of 65 pence per share, the following directors' holdings in Ordinary Shares have changed as set out below:
More information

Back to press releases
  • Email alerts

    Stay up to date and register to receive the latest News and Press Releases by email.

    Email alerts RSS